A Study to Investigate the Efficacy of AlphaWave® L-Theanine on Stress

Inclusion Criteria: * Males and females between 18 and 65 years of age, inclusive * BMI between 18.5 to 29.9 kg/m2, inclusive * Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, total endometrial ablation) or have been post-menopausal for at least 1 year prior to screening OR, * Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening * Individuals with moderate stress as determined by the Perceived Stress Scale (scores ranging from 14 - 26 are considered moderate stress) * Have a regular sleep-wake cycle with a bedtime between 9:00 pm and 12:00 am and receive between 7 and 9 hours of sleep for at least 3 weeks prior to baseline * Agrees to maintain current sleep schedule throughout study * Agrees to maintain current levels of diet, supplements, and exercise until the end of the study * Agrees to refrain from exercising 24-hours prior to the visits * Agrees to abstain from using hair products on the day of visits * Willingness to complete questionnaires, records, diaries associated with the study, and to complete all clinic visits * Healthy as determined by medical history, laboratory results, and physical exam as assessed by the QI Exclusion Criteria: * Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial * Clinically significant abnormal laboratory results at screening as assessed by the QI * Participants who have a known allergy to the test material's active or inactive ingredients * Current employment that calls for rotating shift work or shift work that will disrupt normal circadian rhythm or have worked shift work in the last 3 weeks * Travelled across 1 or more time zones in the last 3 weeks and/or is anticipating more travel * Self reported epilepsy and/or seizures * Type I or Type II Diabetes * Unstable metabolic disease or chronic diseases as assessed by the QI * Current or history of any significant disease of the gastrointestinal tract * Hypertension treated with medication or supplements or untreated hypertension * Self reported anxiety or depression * Significant cardiovascular event in the past 6 months as assessed by the QI * Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI * Individuals with an autoimmune disease or are immune-compromised * History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom-free for 6 months * Self reported current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI * Self reported confirmation of medical or neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation * Self reported blood/bleeding disorders that will have an effect on safety outcomes as assessed by the QI * Alcohol or drug abuse within the last 12 months * High alcohol intake (\>2 standard drinks per day) * Use of medicinal cannabinoid products * Chronic use of cannabinoid products (\>2 times/week). Occasional use to be assessed by the QI on a case by case basis * Use of tobacco and nicotine-containing products within 60 days of baseline * Current use of prescribed medications listed: antibiotics, antiepileptics, antiseizure medications, sedatives, hypnotics * Current use of over-the-counter medications, supplements, foods, and/or drinks listed: caffeine, green tea, L-theanine supplements, melatonin supplements, valerian root supplements, GABA supplements, tart cherries/drinks/supplements, amla, ashwagandha, rhodiola, shatavari, ginseng * Blood donation 30 days prior to screening or a planned donation 30-days of the last study visit * Participants in a clinical research trial within 30 days of screening * Individuals who are unable to give informed consent * Any other condition that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant